US vs Canada: Complete Guide to Drug Registration Process – NDA, ANDA, 505(b)(2) vs NDS, ANDS
Last Updated: September 2026 | By PharmaShare.in – Regulatory Affairs Simplified
Drug Registration Procedure in the USA
The Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services regulates the drug approval system in the United States with six product centers including Center for Drug Evaluation and Research (CDER) and Center for Biologicals Evaluation and Research (CBER). The US has evolved from no regulation in the 18th century to one of the most admired regulatory authorities in the world.
The drug registration procedure in the US is majorly categorized into three parts under Section 505 of the Federal Food Drug and Cosmetic Act.
1. 505(b)(1) or New Drug Application (NDA) – For New Chemical Entities
This route is mainly used to get approval for New Chemical Entities (NCE) which contains full reports of investigations of safety and effectiveness.
- Pre-clinical studies
- Phase I to Phase IV clinical study reports
- Full CMC, quality, and manufacturing data
NDA is preceded by the Investigational New Drug Application (IND). It provides 5 years of data exclusivity.
2. 505(b)(2) Application – The Hybrid Pathway
This application is same as a full NDA, except that this NDA is based on investigations relied on by the applicant for approval and for which the applicant has not obtained a right of reference or use. The applicant majorly relies on published literature and FDA’s Federal Register.
3. 505(j) or ANDA or Generic Drug Application
This section is used for obtaining marketing authorization of exact or close copies of already approved drugs (Reference Listed Drug). No clinical trials are required – only bioequivalence (BE) studies.
Types of ANDA Filings: Paragraph I to IV Certifications
| Subsection of 505(j) | Product Type & Strategy | Market Benefit |
|---|---|---|
| Paragraph I | For products for which no patent information is available in the Orange Book | Immediate approval possible |
| Paragraph II | Used for products for which all the applicable patents are expired | Standard generic launch |
| Paragraph III | Used when some or all applicable patents are valid and applicant confirms product will not be marketed till such patents expire | Delayed launch, low risk |
| Paragraph IV | Used when some or all applicable patents are valid and applicant files that it does not infringe those patents or invalidates the granted patents. On successful outcome, generic applicant enjoys 6 month exclusivity. | 180-Day Exclusivity – Highest ROI |
Drug Registration Procedure in Canada
In Canada, the manufacturer may seek authorization to sell the product by filing a submission with the Health Products and Food Branch (HPFB), Health Canada.
1. New Drug Submission (NDS) – Equivalent to US NDA
A New Drug Submission (NDS) typically contains scientific information about the product’s safety, efficacy and quality. It includes results of both pre-clinical and clinical studies. Required for new active substances.
2. Abbreviated New Drug Submission (ANDS) – Equivalent to US ANDA
An ANDS is used for a generic product in Canada. The generic product must be shown to be as safe and efficacious as the Canadian Reference Product, usually established with bioequivalence studies.
3. Supplemental New Drug Submission (SNDS)
A Supplemental NDS (SNDS) must be filed by the manufacturer if certain changes are made to already-authorized products. Such changes might include:
- Dosage form or strength of the drug product
- Formulation or method of manufacture
- Labeling or recommended route of administration
- Expansion of indications (claims or conditions of use)
US FDA vs Health Canada: Key Filing Differences for Generic Companies
Both US and Canada are Zone II stability markets (25°C/60% RH), so you can use the same stability data. This is different from Brazil, Tanzania which need Zone IVb. Develop once as per the most stringent market.
- Reference Product: US needs US RLD from Orange Book, Canada needs Canadian Reference Product (CRP) sourced in Canada.
- eCTD Module 1: Completely different. US needs Form FDA 356h, Patent Certifications, Debarment. Canada needs HC forms and bilingual labeling (English & French).
- Bioequivalence: Both require BE, but Health Canada has specific criteria for critical dose and highly variable drugs.
Frequently Asked Questions (FAQs)
Q1. What is the difference between NDA and ANDA?
NDA is for a new chemical entity with full pre-clinical and clinical trials. ANDA is for a generic copy of an approved drug and only requires bioequivalence studies to prove it is same as the innovator drug.
Q2. What is 505(b)(2) approval pathway?
505(b)(2) is a hybrid NDA where you can rely partly on FDA’s findings or published literature for an approved drug. It is used for modified versions of approved drugs like new dosage form, strength or new indication.
Q3. What is Paragraph IV filing and why is it important?
Paragraph IV is a certification under 505(j) where a generic company challenges an innovator’s patent as invalid or not infringed. The first company to successfully file Paragraph IV gets 180 days of market exclusivity in the US, making it the most profitable generic route.
Q4. What is equivalent to ANDA in Canada?
The equivalent of ANDA in Canada is ANDS – Abbreviated New Drug Submission filed with Health Products and Food Branch (HPFB) of Health Canada to get approval for a generic drug based on bioequivalence.
Q5. Can I use same dossier for US and Canada?
Yes, Module 2 to Module 5 (Quality, Non-clinical, Clinical overviews and BE studies) can be largely same as both are Zone II countries. Only Module 1 needs to be country-specific as per FDA and Health Canada requirements.
The information provided on this page is for educational and informational purposes only. It is not intended to provide regulatory, legal, or compliance advice.
Pharmaceutical regulations including FDA 21 CFR, EU GMP Annexes, ICH Guidelines, EDQM, WHO, and CDSCO requirements are subject to frequent updates and interpretation by regulatory authorities.
Readers are responsible for ensuring compliance with current applicable laws and regulations in their jurisdiction. PharmaShare does not guarantee the accuracy, completeness, or currentness of this content.
This content does not create a consultant-client relationship. For product-specific regulatory strategy, dossier preparation, or inspection readiness, please consult qualified regulatory professionals or contact us directly.
About the Author
Mahummed Asif is a experienced pharmaceutical Quality Assurance professional and publisher of Pharmashare. He has worked with leading Pharmaceutical organizations and has developed extensive expertise in Quality Assurance, deviation management, investigations, CAPA, QMS, Product Life Cycle Management, change control, risk management, validation, product complaints, product recalls, and regulatory compliance. He is passionate about sharing practical pharmaceutical knowledge with professionals, students, and quality practitioners across the industry.